"We are of course very pleased with the broad utilization of the warrants", says Ulf Hannelius, CEO of Diamyd Medical. "The reinforced financial position is vital in sustaining the positive momentum in the development of Diamyd[®] for Type 1 Diabetes."

Final outcome
The final outcome shows that 185,406 warrants were exercised for the subscription of A-shares, corresponding to a total of 92,703 A-shares, and 8,544,994 warrants were exercised for the subscription of B-shares, corresponding to a total of 4,272,497 B-shares. The exercise rate thus amounted to approximately 95 percent. Diamyd Medical will thereby receive issue proceeds of approximately SEK 48 million before deduction of related issue costs.

Delivery of shares
The new shares have been delivered to subscribers' accounts as interim shares (Diamyd Medical IA), which will then be converted into common shares and listed for trading as soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, which is expected to be completed around October 15, 2024.

Number of shares and share capital
Through the warrant exercise, Diamyd Medical's share capital will increase by 442,724.0830 SEK, from SEK 10,114,030.0533 to 10,556,754.1362 SEK, and the number of shares will increase by 4,365,200 shares, from 99,722,978 shares to 104,088,178 shares, meaning that the total number of A shares after the warrant exercise will be 2,988,496 and the total number of B shares will be 101,099,682.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the exercise of warrants of series TO 3 and Aqurat Fondkommission AB has been appointed as Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd[®] is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company's prospective European Phase IIb trial, where Diamyd[®] was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd[®]. Diamyd Medical also develops the GABA-based investigational drug Remygen[®] as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.